Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced

Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer is a phase 2, interventional study registered as NCT07108127 by Peking Union Medical College Hospital, with a registry enrolment figure of 24 participants, started 2025-06-20 and due to reach its primary completion in 2026-12-01. Interventions recorded: Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX. Conditions listed: Rectal Cancer; HER2-positive. Primary outcome: CR. Colorectal eligibility wording from the registry: "Patients with rectal cancer confirmed by histology or cytology; locally advanced (cT3/T4, N+, distance from the lower edge of the tumor to the anal verge ≤ 12 cm) rectal adenocarcinoma (using the 8th edition of the AJCC TNM staging);". Sites: China. No results are recorded here; the registry entry is the source.